Trade Vir Biotechnology, Inc. - VIR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.76 |
| Open | 9.72 |
| 1-Year Change | -4.61% |
| Day's Range | 9.5 - 9.76 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 9.54 | -0.04 | -0.42% | 9.58 | 9.79 | 9.48 |
| Feb 20, 2025 | 9.76 | 0.03 | 0.31% | 9.73 | 9.84 | 9.56 |
| Feb 19, 2025 | 9.82 | 0.24 | 2.51% | 9.58 | 9.93 | 9.58 |
| Feb 18, 2025 | 9.65 | 0.07 | 0.73% | 9.58 | 9.95 | 9.51 |
| Feb 14, 2025 | 9.62 | 0.09 | 0.94% | 9.53 | 9.96 | 9.53 |
| Feb 13, 2025 | 9.54 | 0.41 | 4.49% | 9.13 | 9.64 | 8.97 |
| Feb 12, 2025 | 9.08 | 0.22 | 2.48% | 8.86 | 9.09 | 8.80 |
| Feb 11, 2025 | 9.03 | -0.31 | -3.32% | 9.34 | 9.34 | 8.86 |
| Feb 10, 2025 | 9.35 | -0.48 | -4.88% | 9.83 | 10.00 | 9.23 |
| Feb 7, 2025 | 9.81 | -0.42 | -4.11% | 10.23 | 10.59 | 9.72 |
| Feb 6, 2025 | 10.19 | 0.15 | 1.49% | 10.04 | 10.63 | 9.93 |
| Feb 5, 2025 | 10.01 | 0.33 | 3.41% | 9.68 | 10.26 | 9.68 |
| Feb 4, 2025 | 9.66 | -0.31 | -3.11% | 9.97 | 10.18 | 9.60 |
| Feb 3, 2025 | 9.94 | -0.16 | -1.58% | 10.10 | 10.27 | 9.67 |
| Jan 31, 2025 | 10.35 | 0.06 | 0.58% | 10.29 | 10.59 | 10.11 |
| Jan 30, 2025 | 10.27 | -0.62 | -5.69% | 10.89 | 10.91 | 10.25 |
| Jan 29, 2025 | 10.86 | 0.36 | 3.43% | 10.50 | 10.95 | 10.25 |
| Jan 28, 2025 | 10.55 | 0.40 | 3.94% | 10.15 | 10.73 | 10.06 |
| Jan 27, 2025 | 10.25 | -0.13 | -1.25% | 10.38 | 10.98 | 10.08 |
| Jan 24, 2025 | 10.60 | -0.53 | -4.76% | 11.13 | 11.21 | 10.45 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Vir Biotechnology Company profile
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.| Industry: | Biotechnology & Medical Research (NEC) |
1800 Owens Street
Suite 900
SAN FRANCISCO
CALIFORNIA 94158
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com